Psoriasis beyond the skin: systemic inflammation as a bridge to metabolic and hepatic comorbidities - PubMed

4 days ago

Psoriasis is now recognized as a systemic inflammatory disease, not just a skin condition.
It affects 2-3% of the global population and carries up to a 50% risk of systemic comorbidities.
Key inflammatory mediators like TNF-α, IL-17, IL-23, and IL-6 contribute to both skin symptoms and systemic issues such as insulin resistance and liver inflammation.
Common pathways like TNF-α/NF-κB activation and the IL-23/Th17 axis link psoriasis to metabolic syndrome and MASLD.
Psoriasis patients show high prevalence of obesity, type 2 diabetes, and dyslipidemia, independent of other risk factors.
Treatment should shift from skin-focused to systemic, multidisciplinary approaches, including biologic therapies targeting IL-17 and IL-23.
Early screening, metabolic monitoring, and lifestyle changes are essential for managing psoriasis long-term.

Hasty Briefsbeta